Cargando…

Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient’s plasma

Innovative therapeutic protocols to the rapidly spreading coronavirus disease (COVID19) epidemic is highly required all across the world. As demonstrated by clinical studies, Favipiravir (FVP) and Remdesivir (REM) are new antiviral medicines that are effective against COVID-19. REM is the first FDA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emam, Aml A., Abdelaleem, Eglal A., Abdelmomen, Esraa H., Abdelmoety, Refaat H., Abdelfatah, Rehab M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098531/ https://www.ncbi.nlm.nih.gov/pubmed/35582001 http://dx.doi.org/10.1016/j.microc.2022.107580

Ejemplares similares

Validated spectral manipulations for determination of an anti-neoplastic drug and its related impurities including its hazardous degradation product
por: Naguib, Ibrahim A., et al.
Publicado: (2021)

Development and Validation of Ecofriendly HPLC-MS Method for Quantitative Assay of Amoxicillin, Dicloxacillin, and Their Official Impurity in Pure and Dosage Forms
por: Almalki, Atiah H., et al.
Publicado: (2021)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Quantification of Rifaximin in Tablets by Spectrophotometric Method Ecofriendly in Ultraviolet Region
por: Kogawa, Ana Carolina, et al.
Publicado: (2016)

UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring
por: Matar, Kamal M., et al.
Publicado: (2020)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
por: Bringas, Mauro, et al.
Publicado: (2022)

Simultaneous determination of some antiprotozoal drugs in different combined dosage forms by mean centering of ratio spectra and multivariate calibration with model updating methods
por: Abdelaleem, Eglal A, et al.
Publicado: (2012)

Green chromatographic method for analysis of some anti-cough drugs and their toxic impurities with comparison to conventional methods
por: Abdelaleem, Eglal A., et al.
Publicado: (2018)

Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir
por: Grundmann, Alexander, et al.
Publicado: (2022)

Dexamethasone/remdesivir: Acute pancreatitis: case report
Publicado: (2022)

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
por: El-Awady, Mohamed, et al.
Publicado: (2022)

Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
por: Sood, Shivani, et al.
Publicado: (2021)

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Eco-friendly spectrophotometric methods for determination of remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment
por: Elama, Heba Samir, et al.
Publicado: (2023)

Dexamethasone/propofol/remdesivir: Various toxicities: case report
Publicado: (2021)

Antibacterials/dexamethasone/remdesivir: Lack of efficacy: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Retraction to “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.
por: Curley, Paul, et al.
Publicado: (2021)

Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models
por: Wang, Yining, et al.
Publicado: (2021)

Recyclable Materials for Ecofriendly Technology
por: Fediuk, Roman, et al.
Publicado: (2022)

Dexamethasone/remdesivir: Lack of efficacy and drug withdrawal: case report
Publicado: (2022)

Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry
por: Harahap, Yahdiana, et al.
Publicado: (2023)

Ecofriendly Palladium on Wool Nanocatalysts for Cyclohexene Hydrogenation
por: Ghadamgahi, Sedigheh, et al.
Publicado: (2018)

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
por: Batubara, Afnan S., et al.
Publicado: (2023)

Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models
por: Imam, Mohamed S., et al.
Publicado: (2023)

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
por: Hegazy, Sahar Kmal, et al.
Publicado: (2023)

Comparison of HPLC and UV Spectrophotometric Methods for Quantification of Favipiravir in Pharmaceutical Formulations
por: Bulduk, İbrahim
Publicado: (2021)

Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR
por: Patel, Ravi, et al.
Publicado: (2022)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2021)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2022)

Dexamethasone/remdesivir: Lack of efficacy and off-label use: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021)

REMDESIVIR-ASSOCIATED ASYMPTOMATIC BRADYCARDIA IN AN ICU PATIENT ON DEXAMETHASONE FOR COVID-19
por: HAIDER, MOBEEN, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_avcmdlv0vdguuvoie43kemnfn3